Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer

被引：22

作者：

Schorge, John O. ^{[1
]}

Bregar, Amy J. ^{[2
]}

Durfee, John ^{[3
]}

Berkowitz, Ross S. ^{[4
]}

机构：

[1] Tufts Med Ctr, Boston, MA USA

[2] Massachusetts Gen Hosp, Boston, MA 02114 USA

[3] Boston Med Ctr, Boston, MA USA

[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

来源：

GYNECOLOGIC ONCOLOGY | 2018年 / 149卷 / 03期

关键词：

Primary debulldng; Cytoreductive surgery; Ovarian cancer; ADVANCED-STAGE OVARIAN; PRIMARY CYTOREDUCTIVE SURGERY; ADVANCED EPITHELIAL OVARIAN; COMPUTED-TOMOGRAPHY SCAN; LONG-TERM SURVIVAL; NEOADJUVANT CHEMOTHERAPY; RESIDUAL DISEASE; SURGICAL CYTOREDUCTION; PERITONEAL CANCER; ONCOLOGY-GROUP;

D O I：

10.1016/j.ygyno.2018.03.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Joe V. Meigs was a visionary clinician and an early adopter of radical techniques in the surgical treatment of ovarian cancer. His 1934 textbook "Tumors of the Female Pelvic Organs", consolidated his approach to this "hopeless" disease, with pearls on diagnosis, outcomes, and even speculations about the benefits of minimally invasive surgery. Decades before adjuvant chemotherapy would prove of value, and in an era when sophisticated statistics were unheard of, he nonetheless tried to eke out what benefits he could using the methods available in his time. We transition his original findings and observations through the advent of platinum-based chemotherapy, retrospective cohort studies supporting the benefits of primary debulking, and finally the long-awaited randomized controlled trial. We aim to provide historical context for the underpinnings of how cytoreductive surgery has evolved into its current role in the treatment of advanced ovarian cancer. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：447 / 454

页数：8

共 63 条

[1] Aggressive surgical effort and improved survival in advanced-stage ovarian cancer [J].